Moleculera Labs Inc.
Diagnosing treatable autoimmune neuropsychiatric illnesses
This article was originally published in Start Up
Moleculera Labs Inc. was founded on the theory that sometimes when psychiatric symptoms appear suddenly in a young person and do not respond well to neuropsychiatric drugs, it could be that an infection has sparked an autoimmune attack on the brain and has triggered PANS or PANDAS. The start-up has developed a diagnostic test to determine if an underlying autoimmune problem is at the heart of the neuropsychiatric symptoms.